Palatin Technologies (PTN) Common Equity (2011 - 2026)
Palatin Technologies' (PTN) quarterly Common Equity came in at $10.6 million in Q1 2026, up 265.83% on a YoY basis from $2.9 million in Q1 2025, and down 7.62% quarter-over-quarter from $11.5 million in Q4 2025.
Analysis
Palatin Technologies (PTN) Common Equity (2011 - 2026) Analysis & Trends
Palatin Technologies (PTN) has reported Common Equity for 16 consecutive years, with $10.6 million the latest figure, recorded in Q1 2026.
- For the quarter ending Q1 2026, Common Equity rose 265.83% year-over-year to $10.6 million; the trailing twelve-month figure through Mar 2026 stood at $10.6 million (up 265.83% YoY), and the FY2025 full-year result was -$4.8 million, down 4184.46% from the prior year.
- Common Equity fell to $10.6 million in Q1 2026 per PTN's latest filing, from $11.5 million in the prior quarter.
- Across five years, Common Equity topped out at $28.1 million in Q1 2022 and bottomed at -$11.4 million in Q4 2023.
- Historically, Common Equity has averaged $2.9 million across 5 years, with a median of $396399.0 in 2025.
- The widest YoY moves for Common Equity: up 279.69% in 2025, down 4184.46% in 2025.
- Over 5 years, Common Equity stood at $11.5 million in 2022, then plunged by 198.73% to -$11.4 million in 2023, then jumped by 43.95% to -$6.4 million in 2024, then soared by 279.69% to $11.5 million in 2025, then fell by 7.62% to $10.6 million in 2026.
- According to Business Quant data, Common Equity over the past three periods registered $10.6 million, $11.5 million, and $396399.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Common Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 206.44 Bn | 192.45 Bn | 7.24 Bn | 11.69 Bn |
| 2 | Gilead Sciences | 179.97 Bn | 176.79 Bn | 6.22 Bn | 11.83 Bn |
| 3 | Vertex Pharmaceuticals | 130.57 Bn | 122.72 Bn | 2.84 Bn | 20.25 Bn |
| 4 | Regeneron Pharmaceuticals | 81.63 Bn | 73.63 Bn | 3.93 Bn | 31.71 Bn |
| 5 | Argenx Se | 60.34 Bn | 55.16 Bn | 1.37 Bn | 8.42 Bn |
| 6 | Moderna | 54.37 Bn | 49.23 Bn | 52.00 Mn | 6.76 Bn |
| 7 | Alnylam Pharmaceuticals | 33.07 Bn | 29.76 Bn | 992.69 Mn | 1.35 Bn |
| 8 | Biogen | 31.84 Bn | 30.55 Bn | 1.96 Bn | 18.85 Bn |
| 9 | Roivant Sciences | 29.49 Bn | 29.49 Bn | 1.16 Mn | 4.92 Bn |
| 10 | Palatin Technologies | 46.98 Mn | 46.98 Mn | - | 10.59 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Mar 31, 2026 | 10.59 Mn |
| Dec 31, 2025 | 11.47 Mn |
| Sep 30, 2025 | 396,399.00 |
| Jun 30, 2025 | -4.78 Mn |
| Mar 31, 2025 | -6.39 Mn |
| Dec 31, 2024 | -6.38 Mn |
| Sep 30, 2024 | -7.69 Mn |
| Jun 30, 2024 | -111,497.00 |
| Mar 31, 2024 | 1.58 Mn |
| Dec 31, 2023 | -11.38 Mn |
| Sep 30, 2023 | -6.32 Mn |
| Jun 30, 2023 | -1.98 Mn |
| Mar 31, 2023 | 6.58 Mn |
| Dec 31, 2022 | 11.53 Mn |
| Sep 30, 2022 | 8.45 Mn |
| Jun 30, 2022 | 16.27 Mn |
| Mar 31, 2022 | 28.09 Mn |
| Dec 31, 2021 | 35.20 Mn |
| Sep 30, 2021 | 42.97 Mn |
| Jun 30, 2021 | 49.65 Mn |